Tanabe Pharma reported top‑line Phase III success for dersimelagon (MT‑7117), an oral melanocortin‑1 receptor agonist, in erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP). The Inspire study met its primary endpoint—delaying onset of prodromal photosensitivity symptoms—supporting the drug’s prophylactic mechanism of increasing melanin and pain‑free light exposure. The positive readout positions Tanabe as a leader in a rare disease niche and could create a non‑injectable alternative for patients with severe light sensitivity. Sponsors and payers will now pivot to regulatory filings and commercialization planning for this small‑population indication.